Norwegian SCAD follow-up and outcomes program
Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD Study)
This program will follow adults hospitalized with SCAD in Norway for one year to see if scheduled imaging, tests, and questionnaires identify complications and risk factors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 3 sites (Bergen and 2 other locations) |
| Trial ID | NCT07317323 on ClinicalTrials.gov |
What this trial studies
NOR-SCAD is a multicenter prospective observational cohort enrolling adults hospitalized with angiographically or imaging-confirmed spontaneous coronary artery dissection at major Norwegian hospitals from 2025–2035. Participants are followed for 52 weeks with planned in-person visits at about 8 and 12 weeks and a final phone call at 52 weeks. Evaluations include coronary CT angiography (CTA), cardiac exams, cardiopulmonary exercise testing (CPET), genetic analyses, blood sampling, and structured questionnaires. Primary endpoints are incidence and types of complications and major adverse cardiac events (MACE), with a secondary focus on the diagnostic and follow-up utility of coronary CTA.
Who should consider this trial
Good fit: Adults (≥18 years) hospitalized with angiographically or imaging-confirmed spontaneous coronary artery dissection at participating Norwegian hospitals are ideal candidates.
Not a fit: People with severe kidney failure, severe allergic reactions to contrast, or those not hospitalized with confirmed SCAD are unlikely to benefit from this program.
Why it matters
Potential benefit: If successful, this could help clinicians detect post-SCAD complications earlier and better guide follow-up care to reduce recurrent cardiac events.
How similar studies have performed: Other national and international SCAD registries have improved knowledge of patient characteristics and outcomes, but routine coronary CTA as a follow-up tool remains incompletely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Spontaneous coronary artery dissection Exclusion Criteria: * Severe kidney failure * Severe allergic reaction to contrast
Where this trial is running
Bergen and 2 other locations
- Haukeland University Hospital — Bergen, Norway (Recruiting)
- Akershus University Hospital — Oslo, Norway (Recruiting)
- Rikshospitalet, Oslo University Hospital — Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Mette Elise Estensen, MD., PhD — ProCardio, Kardiologisk avdeling Rikshospitalet, Oslo Univeristy Hospital
- Study coordinator: Anna Louise Astad Sørlie, MD
- Email: anloso@ous-hf.no
- Phone: +47 926 55 483
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.